Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women

Sharif I. Ismail, Christine Bain, Suzanne Hagen

Research output: Contribution to journalArticle

Abstract

Pelvic organ prolapse is common and can be detected in up to 50% of parous women although many are asymptomatic. Oestrogen preparations are used to improve vaginal thinning (atrophy). It is possible that oestrogens, alone or in conjunction with other interventions, might prevent or assist in the management of pelvic organ prolapse, for example by improving the strength of weakened supporting structures. The aim was to determine the effects of oestrogens or drugs with oestrogenic effects alone, or in conjunction with other treatments, both for prevention and treatment of pelvic organ prolapse. We searched the Cochrane Incontinence Group Specialised Register of trials (searched 6 May 2010), MEDLINE (January 1950 to April 2010) as well as reference lists of relevant articles.

Original languageEnglish
JournalCochrane Database of Systematic Reviews
Issue number9
DOIs
Publication statusPublished - 1 Jan 2010

Keywords

  • pelvic organ prolapse
  • menopause
  • oestrogens

Fingerprint Dive into the research topics of 'Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women'. Together they form a unique fingerprint.

  • Cite this